Brain injury resulting from perinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of acute mortality in infants and chronic neurologic disability in surviving children. Recent multicenter clinical trials demonstrated the effectiveness of hypothermia initiated within the first 6 postnatal hours to reduce the risk of death or major neurological disabilities among neonates with HIE. However, in these trials, approximately 40% of cooled infants died or survived with significant impairments. Therefore, adjunct therapies are required to improve the outcome in neonates with HIE. Cord blood (CB) is a rich source of stem cells. Administration of human CB cells in animal models of HIE has generally resulted in improved outcomes and multiple mechanisms have been suggested including anti-inflammation, release of neurotrophic factors and stimulation of endogenous neurogenesis. Investigators at Duke are conducting studies of autologous CB infusion in neonates with HIE and in children with cerebral palsy. These pilot studies indicate no added risk from the regimens used, but results of ongoing placebo-controlled trials are needed to assess efficacy. Meanwhile, further investigations are warranted to determine the best strategies, that is, timing, dosing, route of delivery, choice of stem cells and ex vivo modulations, to attain long-term benefits of CB stem cell therapy.
INTRODUCTION
Hypoxic-ischemic encephalopathy (HIE) is defined as brain injury in newborn infants diagnosed in the immediate postnatal period. HIE is induced by a combination of inadequate blood flow and oxygen delivery to the neonatal brain. HIE occurs in an estimated 2.5 (1.2-7.7) of every 1000 term births in high income countries. 1 Neonates with HIE have low Apgar scores at 5 min, exhibit abnormal neurologic examination, metabolic acidosis and often have seizures, and require respiratory support within the first postnatal hours of life. 2 Neonatal brain injuries are graded in general by Sarnat scores, based on serial neurobehavioral evaluations in the first postnatal days. 3 Neonates with persistent severe encephalopathy (Sarnat III) have a risk of death or significant disability that approaches 100%. Close to half of neonates with moderate encephalopathy (Sarnat II) die or will have significant neuro-behavioral deficits. 4, 5 Cerebral palsy (CP) is a major form of significant morbidity associated with HIE. 1 Children born at term who develop CP following HIE are twice as likely to have a severe composite disability score and three times more likely to die in the first 5 postnatal years than infants with CP attributed to etiologies other than HIE. 6 Hypothermia has been demonstrated to reduce the percentage of deaths or major sensorineural disabilities among the neonates with HIE, and is becoming the standard approach to newborns with HIE worldwide. 7, 8 However, in the clinical trials demonstrating benefit, a significant number of the HIE infants still died or survived with neurologic and functional impairment. 9 Stem cell regenerative therapies offer great promise in a variety of degenerative diseases including neurological disorders. Stem cells from different sources, such as neural stem/progenitor cells derived from either fetal tissue or embryonic stem-induced pluripotent stem cells, MSCs, human umbilical cord blood (HUCB)-derived stem cells or HUCB mononuclear cells, have been utilized in several animal models of neurological diseases. [10] [11] [12] [13] [14] Cord blood (CB) has been clinically proven to be an effective stem cell source to prevent neurological deterioration in patients with inborn metabolic disorders, that is, Krabbe's disease and Hurler's syndrome. 15, 16 A significant advantage of HUCB cells over other sources of stem cells in tissue regeneration is the ready availability of HUCB. This is particularly important for diseases such as HIE, where at least one of the proven windows of opportunity for rescue therapy (hypothermia) is within a few hours after the insult. CB collected shortly after delivery is a rich source for stem and progenitor cells, and requires minimal ex vivo manipulation and no immunosuppression for autologous transplantation, as is the case for neonates with HIE (Table 1) . 17 CB is widely collected for public and private banking, with well-established standard operating procedures. Properly collected CB cells remain viable at room temperature for 48-72 h. When dosed in neonates, red blood cell depletion and volume reduction is necessary to avoid volume overload or polycythemia in newborns infused with autologous cells. 18 The Carolinas Cord Blood Bank has worked with Biosafe to develop specialized bags for short-term storage of red-cell and volume-reduced CB, which allows aliquots of cells to be used prior to freezing (Figure 1a ) and allowing residual cells to be frozen for long-term storage, and thawed and infused after the first few postnatal days of life (Figures 1b-d) .
PATHOPHYSIOLOGY OF HIE HIE in term infants can be briefly defined into two phases of pathologic events, the primary and secondary energy failure with a latency period in between (Figure 2) . [19] [20] [21] The primary energy failure occurs within minutes after initial cerebral ischemia. This phase is associated with acidosis and a rapid depletion of glucose and high-energy phosphates (ATP) in the brain, resulting in acute intracellular derangements, including membrane depolarization, release and blocked re-uptake of excitatory neurotransmitter, defective osmoregulation and inhibition of protein synthesis, ultimately leading to cell death and necrosis. [19] [20] [21] Resolution of hypoxia-ischemia (HI) and resuscitation reverses the primary energy failure and promotes recycling of neurotransmitters. The duration of time for HI to be successfully reversed is likely influenced by maturation, preconditioning events, substrate availability, body temperature, simultaneous disease processes and possibly individual genetic variations. 22 Depending on the extent of the primary energy failure, delayed secondary energy failure may occur after a variable period of time following the initial insult. Secondary energy failure also leads to altered growth factor and protein synthesis, which ultimately adds the ongoing insult of altered brain development to the evolving HI injury without acidosis. [23] [24] [25] [26] [27] [28] More extensive secondary energy failure and disruption of oxidative metabolism worsens the outcome. 29 Much of the later injury after secondary energy failure occur secondary to the process of apoptosis. [30] [31] [32] Although acute cellular necrosis occurs, apoptotic cell death appears to be a more significant contributor to abnormal outcome for the developing brain of the term infant. 33, 34 After the secondary phase of injury, there is another chronic phase of injury where there is further loss of brain cells. 35 Emerging evidence in animal models of neonatal brain injury and evidence from advanced neuroimaging techniques in infants with HIE, suggest that areas of the brain that are connected to areas of initial injury suffer evolving pathology. Functional neuronal development and connectivity deteriorate after acute brain injury in neonates. 36, 37 These more distal and chronic pathologies may be more heavily influenced by inflammation and alteration of growth factors secondary to early neuronal loss.
LIMITED ENDOGENOUS NEUROGENESIS FOLLOWING HYPOXIC ISCHEMIC INSULTS
Endogenous neural stem cells (NSCs) reside in germinal zones in the embryonic and adult central nervous system, including the subventricular zone, the external germinal layer of the cerebellum and the subgranular zone of the dentate gyrus. [38] [39] [40] [41] Accumulating evidence indicates that endogenous neurogenesis and gliogenesis occur in response to experimental models of ischemia, traumatic brain injury and seizures. [42] [43] [44] However, in contrast to adult brains after ischemic injury, where newly generated neurons are predominantly medium-spiny projection neurons, the regenerated neurons in the neonatal striatum, following the asphyxia, are restricted to only calretinin-expressing interneurons. 44 As calretinin interneurons represent only 0.5% of all striatal neurons in the adult rat brain, this study implies a limited regenerative capacity of endogenous neurogensis after neonatal HI brain injuries. Therefore, therapeutic Gunn et al. 46 induced hypothermia in fetal sheep at various times after injury and before and after onset of electrographic seizures in the animals, which predictably occur between 5.5-6 h after injury. Moderate hypothermia when induced by 90 min post reperfusion and continued until 72 h after ischemia, prevented brain injury and improved electroencephalographic recovery. 47 When hypothermia was delayed until 5.5 h after reperfusion, partial neuroprotection was seen. 48 With further delay until after seizures were established (8.5 h after reperfusion), there was no electrophysiological or overall histological protection with cooling. 49 Potential mechanisms of action of hypothermia have been proposed by measuring how the physiologic and anatomic responses to HI were modified by moderate hypothermia (no less than 6 1C below normal). These include faster recovery of high energy phosphate pools, reduction in caspase activation and apoptosis, normalization (rather than decrease) of protein synthesis, reduction in free radicals and modulation of activation of microglia and cytokine production. 33, 50, 51 Another key mechanistic finding for hypothermia's potential as a therapeutic agent for HI brain injury was the reduction in the excitatory neurotransmitter glutamate when hypothermia was used compared with controls. In piglets, a 4 1C temperature reduction attenuated the increase in excitatory amino acids and nitric oxide concentrations in brain extracellular fluid following HI. 52 Four pivotal multicenter clinical trials of hypothermia for neonates with moderate-to-severe HIE (CoolCap, NICHD Neonatal Research Network, Total Body Hypothermia and Infant Cooling Evaluation) have led to widening adoption of cooling as a treatment of choice for term and near-term neonates with HIE. 9 Four published meta-analyses, including a Cochrane review, demonstrated a consistent beneficial effect for moderate hypothermia with reduction of risk of the combined outcome, death or neurodevelopmental impairment at B2 years ( Figure 3 ). All meta-analyses of several main trials and well-described phase I and II randomized studies, which included outcome information, demonstrate consistent relative risk of death or disability of B0.75 and a 95% confidence interval between 0.60 and 0.90.
53-56 The four trials had similar incidence of primary outcome among control groups, and similar incidence of primary outcome among the intervention groups (40-50%). It is however, important to note that hypothermia results in a reduction in risk of death or disability from 58% to only 47%, suggesting the need for adjunct therapies, such as stem cell regenerative therapy.
In the NICHD Neonatal Research Network trial, mortality was reduced in the hypothermia group, 24% compared with 37% in the control group (relative risk 0.68, 95% confidence interval: 0.43-1.01), and the risk of disabling CP was 19.2% for the hypothermia group and 30.0% among the control group for a relative risk of 0.68 and a 95% confidence interval of 0.38-1.22. 56 In the more recently published Total Body Hypothermia trial, mortality was the same for cooled and regular care, but among survivors, the incidence of CP was significantly decreased in cooled infants (28%) as compared with controls (40%) (P ¼ 0.03). 57 The results of multicenter human clinical trials indicate that the critical period for initiation of cooling appears to occur within the first 6 postnatal hours; an on-going NICHD study is examining whether later initiation of cooling, after the first 6 postnatal hours, will be as effective (ClinicalTrials.gov # NCT00614744).
CLINICAL INTERVENTIONS FOR HIE: AUTOLOGOUS CB SCT
Earlier experience with allogeneic unrelated CB transplantation in patients with inborn errors of metabolism demonstrated that CB cells, both hematopoietic and non-hematopoietic in origin, can engraft in the central nervous system, providing the missing enzyme and facilitating neural cell repair. 58 Based on these observations, Sun et al. 59 conducted a pilot study to determine the safety and feasibility of i.v. infusion of autologous CB in 184 pediatric patients who had their CB privately banked at birth and who subsequently experienced various acquired neurological injuries, including 140 with CP. This investigation demonstrated the safety and feasibility of thawed and washed autologous CB infusions in the outpatient setting in these pediatric recipients.
Currently, Cotten et al. have initiated a clinical trial of autologous volume-and red cell-reduced CB infusions in term infants with HIE, along with concurrent whole body cooling. In this clinical trial, fresh red blood cells and volume-reduced CB cells were infused into neonates after diagnosis with HIE, and at 24, 48 and 72 postnatal hours, respectively (NCT00593242) (personal communication with Cotten) . Cell doses ranged from 1 Â 10 7 to 5 Â 10 7 cells per kilogram per dose of cells with 1-4 doses administered to each baby. After volume and red cell reduction, CB cells can be maintained at room temperature for a minimum of 48 h. Evidence suggests viability could extend beyond 72 h, but the current FDA-approved research protocol restricts study dosing to the first 48 h. Cells must be frozen if maintained beyond 48 h. 7 At Duke, there is an extended arm of the HIE study that allows for infusion of cryopreserved CB within the first two weeks of life. To date, one infant in the Duke study of CB cells for HIE has received thawed cells. Preliminary results of this experience have also demonstrated the feasibility and safety of autologous CB transplantation in neonates with HIE. 60 Currently 420 infants have been infused with no apparent safety risks attributable to use of fresh, red blood cells and volume-reduced CB cells revealed to date. After completion of a safety pilot (30 babies), a randomized trial utilizing cooling ± autologous CB infusions is planned. Table 1 summarizes the advantages and disadvantages of CB infusion in neonates with HIE.
This same group has initiated a prospective, randomized, placebo-controlled study of autologous CB infusions in older children (ages 1-6 years) with CP.
CB STEM CELL BIOLOGY
CB is a rich source of stem and progenitor cells. In addition to HSCs, non-hematopoietic stem cell populations exist in CB, including, but not limited to, MSCs and more primitive stem cell populations with multi-lineage differentiation properties, that is, unrestricted somatic stem cells, multi-lineage progenitor cells, embryonic-like stem cells and very small embryonic-like stem cells that have respectively been shown to differentiate into neural cells. 14, 17, [61] [62] [63] [64] [65] MSCs, which can also be isolated from BM and other sources, have been demonstrated to exert neuro-protection in HIE animal models. [66] [67] [68] [69] [70] Cell lines with NSC properties have been established from HUCB following immune-depletion of the CD34-positive cells from CB and spontaneous aggregation and differentiation with stimulation by epithelial growth factor. 71 When such CB-NSCs were seeded on human-originated biodegradable scaffold, they were able to differentiate into neurons, form functional circuits and generate spontaneous field/action potentials. 72 Recently, Tracy et al.
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demonstrated that oligodendrocyte progenitors could also be isolated and expanded ex vivo from human CB. In addition, monocytes constitute about 5-10% of HUCB mononuclear cells and bear unique features in their immaturity in the immune and inflammation stimulatory functions, as compared with those originating from BM or peripheral blood. 74 Monocytes have also been shown to participate in angiogenesis via several mechanisms. 74 Such angiogenic and anti-inflammatory effects have likely had an important role in CB regenerative therapy, especially in ischemic diseases.
The composition of multiple populations of stem or progenitor cells underscores the regenerative potential of CB, meanwhile predicting their mechanisms of action to be multifactorial. This concept has been supported by recent preclinical study comparing the effectiveness of freshly isolated CB mononuclear cells with other neural committed stem/progenitors in experimental rats 3 days after focal brain injury. 75 The highest effectiveness, demonstrated by enhanced functional recovery and reduced lesion volume, was observed in the group treated with CB mononuclear cells.
ANIMAL MODELS OF HUMAN CB TRANSPLANTATION FOR HIE
Animal models of HIE include studies in rabbits (Tan), macaques (Juul) and rodents (Vannucci) , etc. [76] [77] [78] [79] [80] Many of the animal studies reviewed here have been based on the Vannucci model in rodents. This model involves unilateral carotid artery ligation followed by a period of moderate hypoxia in neonatal rats or mice. 80 The procedure is typically conducted in the 7-day-old rodent (P7), an age at which cortical maturity roughly corresponds to 34-36 weeks gestation in humans. 81 Cortical maturity of the P12-13 rat is comparable to term humans. 82, 83 Thus, the models reviewed so far represent an acute and localized HI insult and at an age equivalent to a somewhat preterm gestation human. Table 2 summarizes the results of human CB transplantation in animal models of HIE. Meier et al. 84 first reported the results of HUCB mononuclear cell administration in P7 rats. In this study, i.p. injection of 1 Â 10 7 HUCB mononuclear cells 24 h after HI led to a reduced spastic paresis 2 weeks after the insult. Migration of the transplanted cells to the damaged hemisphere was observed but there was no apparent evidence for neural cell differentiation or reduction in brain atrophy 21 days after administration. Recently, this group demonstrated that HUCB given 24 h after HI significantly preserved somatosensory function on the side of the lesion without structural evidence of improvement. 85 Pimentel-Coelho et al., 86 using 2 Â 10 6 cryopreserved-thawed HUCB cells i.p. in P7 rats 3 h after HI, also showed homing or engraftment of trivial numbers of HUCB cells in the lesion and improvements in sensorimotor reflexes 4 days after HI, but not at 2 and 7 days. The improved outcomes were associated with reduced caspase-3 cleavage, activated microglia and macrophages at various brain regions. This study suggested that CB cells have anti-apoptotic and anti-inflammatory properties.
Yasuhara et al. 87 demonstrated that i.v. administration of 15 000 HUCB cells 7 days after HI in P7 rats, with or without mannitol administration, was associated with improvement in motor asymmetry and coordination 7 and 14 days later. The time spent on rotarod test showed a small improvement with CB cells and a slightly greater improvement when combined with mannitol. This same group had previously shown no improvement in rotarod tests from intra-hippocampal administration of 200 000 human multipotent progenitor cells derived from BM, implying a superior function of CB cells. 69 Only a few transplanted CB cells (2-25 per brain) were found in the entire brain following HUCB administration, suggesting that the mechanism of action is more from a neurotrophic effect, perhaps on endogenous cells. 87 Mannitol has been used to facilitate the delivery of various drugs directly to the brain, by producing osmotic shrinking of the endothelial cells and mechanical separation of the tight junctions that form the blood-brainbarrier (BBB). This study by Yasuhara et al. demonstrated a cooperative increase on the levels of neural growth factor in the central nervous system 3 days after CB infusion and mannitol treatment, suggesting a potential therapeutic benefit of combined BBB permeation via mannitol and CB infusion for the treatment of neonatal HIE; however, mannitol is not used clinically in treatment after HIE. 87 De Paula et al. 88 found that i.v. injection of 1 Â 10 7 HUCB cells 24 h after HI in P7 rats was associated with small number of cells in the brain and no significant improvement in either volume of infarction or behavioral tests, including locomotion, balance, limb asymmetry and spatial memory 3 weeks later. The authors suggested that the degree of brain damage, injected cell dose, length of follow-up for evaluation and route of delivery might have influenced the outcome.
Human CB transplantation studies have also been conducted in adult animals following experimentally induced ischemic injury. [89] [90] [91] [92] [93] [94] [95] [96] Beneficial effects have generally been observed determined by behavioral improvements in most cases, but also by the reduction in lesion size in some studies. Owing to the poor survival of the transplanted cells and little evidence for neural differentiation, bystander effects have been postulated to be the main mechanisms for functional recovery after CB transplantation, including release of neurotrophic factors to stimulate endogenous neurogenesis, prevention of cell loss and immunomodulation (Figure 4) . 17, 97, 98 It has also been suggested that stem cell engraftment in the brain may not be critical for functional recovery provided that neurotrophic factors secreted by exogenous cells could reach the ischemic brain. 93 However, in most of the animal studies, human CB cells were injected without prior or concomitant immunosuppression. Although immunologic tolerance of CB cells has been documented, possibly mediated by diminished cytotoxic responses of the host, 99, 100 and were further supported by the sporadic detection of the human cells in the ipsilateral brain of the above experimental animals, [84] [85] [86] [87] [88] the potential effect of immunosuppressive treatment on the engraftment of the human cells has not been extensively investigated. Therefore, such xenotransplantation studies do not recapitulate the clinical setting of autologous CB transplantation in neonates with HIE. Nevertheless, the functional recovery in the experimental animals, possibly mediated by trophic effects of CB cells, substantiate the ongoing investigation of CB cell therapy for neonatal HIE.
ANIMAL MODELS OF OTHER SCT FOR HIE
Other stem cells that have been tested in animal models of HIE include multipotent progenitors (MAPCs), MSCs and NSCs (Tables 3 and 4 ). Multiple sources of multipotent stem cells, either syngeneic or allogeneic, injected at different days and via different Alleviation of brain tissue injury, however, was only observed in some of the studies; the difference may be related to the severity of brain injury: a better outcome seems to be associated with a shorter period of hypoxia treatment. 67, 101, 103 Engraftment of the multipotent stem cells has also been observed. However, differentiation has mainly been limited to GFAP þ astrocytes.
101-103
The inefficiency to undergo in vivo differentiation has also been observed following delivery of NSCs in the injured postnatal neocortex in animal models of HIE. Lee et al. 104 reported that the majority of the donor cells remained undifferentiated or became astroglia, with only about 5% and 4% differentiation into neurons and oligodendrocytes, respectively. In an adult ischemic brain injury model, under the condition of immunosuppression either transiently or throughout the experiment, Nodari et al. 105 reported that immortal human NSCs could differentiate toward astroglial and neuronal lineage, but not oligodendrocytes in the ischemic brain. Thus, it appears that the injured brain microenvironment does not favor engraftment and regeneration of the transplanted cells. Strategies aimed at optimizing the microenvironment for both endogenous and exogenous neurogenesis would potentially enhance the benefits of stem cell regenerative therapy. In a previous study, mouse NSCs were seeded onto a polyglycolic acid polymer scaffold and implanted into the infarction cavities of mouse brains at 1 week after the HI injury. 106 This manipulation promoted reciprocal interactions between host and transplanted NSCs, and resulted in a substantial reduction in parenchymal loss and reconstitution of anatomical connections. Other strategies include delivery of stem cells overexpressing neurotrophic factors and lineage predisposition of stem cells before transplantation. 104, [107] [108] [109] [110] Route of stem cell administration Migration of various types of stem cells to the site of injury has been documented in HIE animal studies following either systematic or local injection. 70, 84, 111, 112 Considering the volume of CB and the young age of the neonates with HIE, i.v. infusion is a safe and effective method of administration, even though it means that only a limited number of cells may arrive in the damaged brain. 113 As compared with i.v. injection, carotid artery injection of neural progenitors, mainly conducted in the adult stroke model, resulted in a higher level of cellular survival and engraftment in the injured brain. 113, 114 However, the risk of approach via carotid injection has been reduction in cerebral blood flow and consequently microstrokes. 114, 115 Such an approach, via the carotid, is much too risky to consider at this early stage of clinical trials of cells for neonates with HIE. Nasal administration may represent another novel route of stem cell delivery to the ischemic brain in newborns. 101 Intranasal injection of MSC 10 days after HI in the P9 mice resulted in engraftment of MSCs in the affected hemisphere, improved sensorimotor function and a reduction in brain lesion size. 101 The method involving intra-cerebral injection of stem cells has been utilized in numerous animal studies, especially with expanded cell populations such as NSCs and MSCs. A large number of cells can be delivered locally to desired brain regions, which may result in a direct effect on endogenous neurogenesis. 116 Local delivery of multipotent progenitor cells into the hippocampus, the region that controls motor function and meanwhile is highly vulnerable to HI insult, has been demonstrated to ameliorate the motor deficits in the rat model of HIE. 69 The benefits have been partially attributed to direct stimulation of endogenous neurogenesis in the stem cell niche (dentate gyrus) that is adjacent to the injection site. 69 However, it has to be noted that the same authors also reported a similar beneficial effect of multipotent progenitor cells in the rat HIE model, following i.v. injection. 70 Meanwhile, the safety of such an invasive procedure has to be carefully evaluated before its application in clinical studies.
Timing of SCT It has been reported that endogenous cell death is prominent in the first day after HI insult and the endogenous repair mechanisms start to be active by day 2 and peaked at day 3. 67 Therefore, the first few days after the HI insult may represent the window of maximum growth-promoting capacity in the brain and may also favor the regenerative potential. Supportively, transplantation of 100 000 murine MSCs to the ipsilateral hemisphere of the P9 mouse at day 3 post HI resulted in not only functional improvements, but also increased cell proliferation and differentiation (toward neurons and oligodendrocytes) and reduction in the lesion volume at 21 days after the insult. 67 Meanwhile, a recent report on NSC transplantation indicated that engraftment of stem cells was maximal 3-7 days following HI, however, the functional outcomes were not reported. 104 In animal models of HIE, stem cells have been transplanted 3 h, 24 h, 3 days, 7 days and 10 days, respectively, post the HI insult, with different degrees of beneficial outcome. 67, 68, 70, 84, 86, 87, 106 As most of these studies have more than one variable, it is difficult to conclude the best timing for stem cell therapy. It is possible that the function of stem cells varies at different stages of brain injury. Early interventions are likely important to reduce neurological injury by suppressing inflammation and apoptotic cell death, while transplantation in a chronic stage may improve long-term neurological functions. Consistently, a recent study comparing the effects of single (day 3 following HI insult) and repeated (second treatment on day 10) MSC treatment indicated that each MSC treatment resulted in distinct functional outcomes. 68 The first MSC 68 There also appeared to be a crosstalk between the brain milieu, for example, neural and endothelial cells, and the transplanted cells, as determined by the differential genomic responses of MSCs to the extracts from the ischemic mouse brains with or without prior MSC injection. 68 
CONCLUSION
Neonatal HIE has been associated with a high risk of death and major neurological disabilities. Hypothermia initiated within the first 6 postnatal hours has produced consistent beneficial outcomes among neonates with HIE. However, there is still a large percentage of neonates with HIE that died or developed significant disabilities. The safety and feasibility of autologous CB transplantation in pediatric patients with acquired neurological disorders has recently been demonstrated. The ongoing clinical trial on autologous CB cells in infants with HIE within a few hours or days after diagnosis will further reveal hints of the potential for therapeutic efficacy of CB in the acute phase of HIE. In addition, animal studies have generally demonstrated benefits of different types of stem cells, with varied dosing, timing and methods of administration. CB, owing to its complex composition, may have multifactorial benefits. As the function of stem cells could be influenced by the progression of the disease and the endogenous microenvironment, a combined therapy should be considered in the future in the clinical setting. Multiple dosing, supplementation of additional stem cell sources and modulations on the host microenvironment will likely improve the repair and regeneration of the damaged brain. Additional studies to determine best dose, best administration route and best cell source(s) will be required to determine the potential benefit of CB therapy in infants with HIE. 
